Catalog No.
Product Name
Application
Product Information
Citations
-
PPARγ Agonist
Methyl oleanonate is a natural triterpene that acts as an agonist for peroxisome proliferator-activated receptor gamma (PPARγ). Isolated from Pistacia lentiscus var. Chia, this compound exhibits significant anti-cancer properties and is of interest in research focused on metabolic regulation and tumorigenesis. Its ability to modulate PPARγ makes it a valuable tool for investigating pathways related to metabolism and cancer therapeutics. -
PPARγ Inhibitor
PPARγ phosphorylation inhibitor 1 is a selective inhibitor targeting Peroxisome Proliferator-Activated Receptor gamma (PPARγ). It effectively inhibits CDK5-mediated phosphorylation of PPARγ at Ser273 with an IC50 of 160 nM, demonstrating a binding affinity with an IC50 of 24 nM. This compound exhibits minimal PPARγ agonistic activity in reporter gene assays, making it a valuable tool for studying the role of PPARγ phosphorylation in metabolic disorders and antidiabetic research applications. -
PPAR Agonist
Palmitoyllactic acid is a PPAR agonist that exhibits lipogenic activity. It has been shown to induce a brown fat-like phenotype in 3T3-L1 adipocytes by enhancing the expression of key genes associated with brown/beige adipocyte differentiation, including Prdm16 and Pgc1a. Additionally, palmitoyllactic acid significantly promotes adipogenesis in conjunction with dexamethasone. This compound is valuable for research into obesity and metabolic disorders. -
PPARα Agonist
PPARα Agonist 6 functions as an agonist of peroxisome proliferator-activated receptor alpha (PPARα). It plays a critical role in the regulation of lipid metabolism and can be utilized in research focused on dyslipidemia and related metabolic disorders. This compound supports studies aimed at understanding the molecular pathways involved in lipid homeostasis and the therapeutic potential of targeting PPARα. -
PPARγ Agonist
9-Octadecynoic acid is a selective agonist of peroxisome proliferator-activated receptor γ (PPARγ), known to modulate gene expression involved in lipid metabolism and insulin sensitivity. This compound demonstrates strong biological activity in cellular systems, making it a valuable tool for studying metabolic disorders and obesity-related research. Its role as a PPARγ activator enables investigations into the mechanisms of action related to glucose homeostasis and fatty acid storage. -
PPARγ agonist
Farglitazar is a potent PPARγ agonist that plays a crucial role in regulating glucose metabolism. This compound is particularly relevant in the study of type 2 diabetes, exhibiting significant glycemic control effects. Its ability to modulate insulin sensitivity makes it a valuable tool for research into diabetes management and related metabolic disorders. -
PPARG Inverse Agonist
BAY-5094 is an inverse agonist of the peroxisome proliferator-activated receptor gamma (PPARG). This compound exhibits oral bioactivity and has potential applications in the study of luminal bladder cancer. Its mode of action allows for investigation into the role of PPARG in tumorigenesis and cancer progression. -
PPAR-γ Ligand
Glycyrin is a potent ligand for the peroxisome proliferator-activated receptor gamma (PPAR-γ). This compound has demonstrated the ability to lower blood glucose levels in genetically diabetic mice, indicating its potential role in diabetes research. Additionally, glycyrin exhibits antibacterial properties, making it applicable in studies related to infectious diseases. -
PPARα/γ Agonist
Wistin is a selective agonist of peroxisome proliferator-activated receptors (PPARα and PPARγ), derived from the roots of Caragana sinica. It demonstrates significant biological activity in regulating lipid metabolism and glucose homeostasis. Wistin is commonly utilized in research focused on metabolic disorders, diabetes, and cardiovascular diseases, providing insights into the therapeutic potential of PPAR modulation. -
PPAR Ligand
9-HEPE is a PPAR ligand derived from the oxidation of Eicosapentaenoic acid, comprising a racemic mixture of 9(R)-HEPE and 9(S)-HEPE. It enhances fatty acid oxidation, promotes adipogenesis, and increases glucose uptake through the activation of peroxisome proliferator-activated receptors (PPARs) in vivo. This compound is instrumental for research applications focusing on metabolic regulation and disorders related to obesity and insulin sensitivity. -
PPARalpha/PPARgamma Activator
20-Carboxyarachidonic acid is an endogenous dual activator of PPARalpha and PPARgamma. As a stable metabolite of 20-HETE, it plays a significant role in regulating lipid metabolism and inflammation. This compound is utilized in research exploring metabolic disorders, cardiovascular diseases, and the modulation of inflammatory responses. -
PPARγ Agonist
10-Nitrolinoleic acid is a potent agonist of peroxisome proliferator-activated receptor γ (PPARγ). It demonstrates the ability to compete with [3H]Rosiglitazone for binding to PPARγ, achieving an IC50 value of 0.22 μM. This compound is valuable for research focused on metabolic regulation and the modulation of insulin sensitivity, making it relevant in studies of obesity and type 2 diabetes. -
PPAR-γ Activator
SP4e is a selective activator of peroxisome proliferator-activated receptor gamma (PPAR-γ), exhibiting an EC50 of 739 nM in HK-2 cells. This compound displays significant biological activity by lowering blood glucose levels and reducing lipid peroxidation, while simultaneously enhancing glutathione levels and catalase activity in Swiss albino mice. SP4e can be employed in research focused on metabolic disorders, oxidative stress, and related therapeutic pathways. -
ABCA1 Inducer/PPARs Agonist
E17241 is an inducer of ATP-binding cassette transporter A1 (ABCA1) that significantly enhances ABCA1 protein levels in RAW 264.7 macrophages. It also acts as an agonist for peroxisome proliferator-activated receptors (PPARs), contributing to metabolic regulation. Notably, E17241 has demonstrated the capability to reduce plasma glucose levels and body weight in KKAy diabetic mice subjected to a high-fat and high-glucose diet, making it a valuable reagent for research on lipid metabolism and diabetes management. -
PPAR-α/δ Inhibitor
Anti-NASH agent 1 is a potent PPAR-α/δ inhibitor that effectively targets nonalcoholic steatohepatitis (NASH). This compound has demonstrated significant efficacy in improving hyperlipidemia, liver fat degeneration, and liver inflammation in a methionine-choline deficiency (MCD) induced NASH mouse model. Additionally, Anti-NASH agent 1 exhibits low liver toxicity while providing protective effects on liver health, making it a valuable tool for research into metabolic disorders and liver diseases. -
PPARγ agonist
Amorfrutin B is a potent agonist of peroxisome proliferator-activated receptor gamma (PPARγ), with Ki values of 19 nM and an EC50 of 73 nM, indicating strong bioactivity. This compound exhibits hypoglycemic effects and provides neuroprotective benefits, making it valuable for research in metabolic disorders and neurobiology. Its oral activity further enhances its potential for in vivo studies focused on PPARγ modulation. -
PPARγ Inhibitor
Soyasaponin Aa is a PPARγ inhibitor that demonstrates significant anti-obesity effects in 3T3-L1 adipocytes by downregulating the activity of peroxisome proliferator-activated receptor γ. Its biological activity supports research into mechanisms of adipogenesis and metabolic regulation. Soyasaponin Aa is useful in studies aimed at understanding the therapeutic potential of targeting PPARγ in obesity-related conditions. -
PPAR Agonist
Naveglitazar is a non-thiazolidinedione peroxisome proliferator-activated receptor (PPAR) α-γ dual agonist, exhibiting a predominant effect on PPARγ. It has demonstrated significant glucose-lowering activity in various animal models, making it a valuable tool for research into insulin sensitivity and metabolic diseases. Its dual action on PPARα and PPARγ positions Naveglitazar as a potential candidate for investigating therapeutic approaches for type 2 diabetes and related metabolic disorders. -
PPAR Activator
13-Oxo-9E,11E-octadecadienoic acid acts as a potent PPARα activator and is derived from tomato juice. This compound has demonstrated the ability to reduce plasma and hepatic triglyceride levels in obese diabetic mouse models. Its applications in research include the study of metabolic disorders and potential therapeutic strategies for obesity-related conditions. -
PPARγ Agonist
PPARγ Agonist 11 is a selective agonist of the peroxisome proliferator-activated receptor gamma (PPARγ) with an EC50 of 0.1 μM. This compound is instrumental in the study of metabolic disorders, including obesity and type 2 diabetes, by activating PPARγ pathways involved in glucose and lipid metabolism. Its role in modulating insulin sensitivity makes it a valuable tool for research into therapeutic interventions for metabolic diseases. -
PPARδ Activator
E0924G is an orally active PPARδ activator with an EC50 of 2.82 μM. This compound effectively induces the upregulation of osteoprotegerin (OPG) with an EC50 of 0.29 μM, demonstrating significant inhibition of RANKL-induced osteoclast differentiation and F-actin ring formation in RAW264.7 macrophages. E0924G has potential applications in research focused on bone density regulation and the treatment of bone loss in models of ovariectomized and age-related osteoporosis. -
PPARγ Ligand
SKLB102 is a potent PPARγ ligand that demonstrates high affinity for the nuclear receptor. It effectively reduces fat deposition and offers protective effects against non-alcoholic fatty liver disease (NAFLD) by modulating adipocytokine expression and preventing insulin resistance. This compound is valuable for research focused on metabolic disorders and the regulation of lipid metabolism. -
PPAR-δ Agonist
Seladelpar (lysine) is a selective agonist of the PPAR-δ receptor, demonstrating high potency with an EC50 of 2 nM. It exhibits over 750-fold and 2500-fold selectivity towards PPAR-α and PPAR-γ, respectively. Seladelpar (lysine) is primarily utilized in research focused on primary biliary cholangitis and related metabolic disorders, providing valuable insights into lipid metabolism and liver function. -
PPARG Agonist
2-Ethylhexyl diphenyl phosphate is a PPARG agonist with an effective concentration (EC20) of 2.04 µM. It also demonstrates inhibitory activity on ERRγ transcriptional activity with an IC50 of 1.3 µM. This compound is known to upregulate 3β-HSD1, enhance human chorionic gonadotropin (hCG) production, and stimulate progesterone secretion. It serves as a valuable tool for investigating mechanisms of female reproduction and fetal development in biochemical research. -
PPARγ Activator
5-Aminosalicylic acid-13C6 hydrochloride is a labeled variant of 5-Aminosalicylic acid, functioning primarily as a PPARγ agonist. This compound exhibits significant biological activity by inhibiting p21-activated kinase 1 (PAK1) and the transcription factor NF-κB. It is commonly utilized in research concerning metabolic disorders, inflammation, and immune response pathways. -
PPAR
Naveglitazar racemate is a non-thiazolidinedione agonist targeting peroxisome proliferator-activated receptors (PPAR) α and γ, with a dominant effect on PPAR γ. This compound has demonstrated significant glucose-lowering activity in various animal models, making it a valuable tool for research in metabolic disorders. It is applicable in studies focused on diabetes and obesity, particularly in understanding the mechanisms of dual PPAR activation and its implications for therapeutic strategies. -
PPAR Agonist
PPAR Agonist 1 is a selective agonist of peroxisome proliferator-activated receptors (PPAR) α and γ. It demonstrates significant biological activity in the regulation of glucose and lipid metabolism, effectively lowering blood glucose and cholesterol levels while promoting weight reduction. This compound is suitable for research applications targeting metabolic disorders and investigating the effects of PPAR activation on energy homeostasis. -
PPARα Agonist
PPARα Agonist 2 is a potent and selective agonist specifically targeting the peroxisome proliferator-activated receptor alpha (PPARα) with an EC50 of 37 nM. It demonstrates more than 2,700-fold selectivity over other PPAR isoforms. This compound is valuable for research focused on retinal disorders and other related metabolic studies. -
Dual ACLY inhibitor/PPARα Agonist
BGT-002 is a potent dual inhibitor of ATP-citrate lyase (ACLY) and a peroxisome proliferator-activated receptor alpha (PPARα) agonist. This compound effectively reduces lipogenesis by inhibiting fatty acid synthesis and enhancing lipid efflux. BGT-002 has shown efficacy in improving metabolic dysfunction-related steatohepatitis and hyperlipidemia in vivo, making it a valuable reagent for research into hypercholesterolemia and related metabolic disorders. -
PPAR-δ Agonist
Seladelpar Lysine dihydrate is a potent PPAR-δ agonist with an EC50 value of 2 nM. This compound exhibits significant specificity, demonstrating over 750-fold selectivity for PPAR-δ compared to PPARα and over 2500-fold selectivity relative to PPARγ. Research applications include the investigation of primary biliary cholangitis and the modulation of metabolic conditions, including the normalization of hyperglycemia, hyperinsulinemia, serum lipids, and cholesterol levels. Additionally, Seladelpar Lysine dihydrate has been shown to ameliorate nonalcoholic steatohepatitis in mouse models. -
PPARδ/γ Agonist
DB-959 is a potent agonist of the Peroxisome Proliferator-Activated Receptors delta (PPARδ) and gamma (PPARγ). It has been shown to enhance spatial learning and memory in mice models induced by Streptozotocin, indicating its potential therapeutic application in Alzheimer's disease. This compound is valuable for research focused on neurodegenerative disorders and metabolic regulation. -
PPAR Agonist
Deutaleglitazar is a selective agonist of dual peroxisome proliferator-activated receptors, PPARα and PPARγ. This compound exhibits significant biological activity in regulating lipid metabolism and glucose homeostasis, making it relevant for research in diabetes and metabolic syndrome. Its dual action supports investigations into therapeutic strategies for obesity-related conditions and cardiovascular diseases. -
PPARα Agonist
GW 590735 sodium is a selective agonist of peroxisome proliferator-activated receptor alpha (PPARα), known for its role in regulating lipid metabolism. This compound effectively elevates high-density lipoprotein (HDL) cholesterol levels while reducing low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) cholesterol, alongside a significant decrease in triglyceride levels. GW 590735 sodium demonstrates potential in research applications targeting dyslipidemia and metabolic disorders. -
PPARγ Agonist
PPARγ Agonist 10 is a selective agonist of the peroxisome proliferator-activated receptor gamma (PPARγ). It enhances insulin secretion, promotes glucose uptake, and improves insulin sensitivity in βTC6 cell lines. This compound is valuable for research in metabolic disorders, particularly type 2 diabetes and obesity, facilitating the study of PPARγ's role in glucose homeostasis and metabolic regulation. -
PPAR Agonist
Inolitazone hydrochloride hydrate is a high-affinity agonist of the peroxisome proliferator-activated receptor gamma (PPARγ), exhibiting an EC50 value significantly lower than that of Rosiglitazone. It selectively activates PPARγ without inhibiting RIE cells lacking this receptor. This compound is primarily utilized in cancer research, providing insights into the mechanisms of PPARγ in tumor biology and potential therapeutic applications. -
PPARγ Agonist
PPARγ Agonist 4 (Compound 18b) is a potent and selective agonist targeting the peroxisome proliferator-activated receptor gamma (PPARγ). This compound demonstrates notable antitumor activity specifically in combination with Imatinib, highlighting its potential in enhancing therapeutic effects in resistant tumor models. Furthermore, PPARγ Agonist 4 is non-cytotoxic to both resistant and non-resistant cell lines, making it a valuable tool for research applications aimed at understanding PPARγ modulation in cancer therapy. -
PPARδ Agonist
PPARδ Agonist 12 is a selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). This compound demonstrates the ability to inhibit the production of pro-inflammatory factors and nitric oxide. Additionally, PPARδ Agonist 12 effectively reduces macrophage infiltration at sites of inflammation, making it a valuable tool for studying inflammatory processes and their regulation in various research applications. -
PPAR Agonists
SB-219994 is a selective agonist of peroxisome proliferator-activated receptors (PPARs). It demonstrates potent anti-inflammatory activity by inhibiting airway neutrophilia and reducing associated chemoattractants and survival factors. This compound is valuable for research applications targeting inflammatory diseases and exploring the role of PPARs in immune responses. -
CB1 Antagonist/PPARα Agonist
OLHHA is a dual CB1 receptor antagonist and PPARα agonist. This compound demonstrates notable activity in inhibiting alcohol intake with an EC50 value of 0.2 mg/kg. Additionally, OLHHA effectively reduces hepatic lipid accumulation and circulating triglyceride levels, exhibiting anti-steatotic properties. Its mechanism and effects make it a valuable tool for research into non-alcoholic fatty liver disease (NAFLD). -
PPARα Agonist
Ciprofibrate Impurity A is a notable impurity of Ciprofibrate, which serves as a potent agonist of peroxisome proliferator-activated receptor alpha (PPARα). This compound enhances the phosphorylation levels of PPARα, thereby influencing lipid metabolism and glucose homeostasis. Ciprofibrate Impurity A is relevant for research applications focused on metabolic disorders, inflammation, and other PPARα-related signaling pathways. -
PPAR Agonist
BMS711939 is a selective agonist of peroxisome proliferator-activated receptor α (PPAR α), demonstrating an EC50 of 4 nM for human PPARα and 4.5 μM for human PPARγ. This compound shows promising pharmacokinetic properties in rat models and is known to elevate HDL cholesterol levels while decreasing LDL cholesterol and triglycerides. BMS711939 serves as a valuable tool for investigating lipid metabolism and the physiological effects of PPAR activation. -
PPAR Activator
Peliglitazar is a dual alpha and gamma peroxisome proliferator-activated receptor (PPAR) activator. It promotes insulin sensitivity and lipid metabolism, making it valuable in the study of metabolic disorders such as type 2 diabetes and obesity. Research applications include investigating the molecular mechanisms of PPAR signaling and developing therapeutic strategies for related conditions. -
PPAR-γ Agonist
MBX-102 acid is a selective partial agonist of PPAR-γ (Peroxisome Proliferator-Activated Receptor Gamma). This compound exhibits strong binding to plasma proteins, primarily serum albumin, which may influence its pharmacokinetics. MBX-102 acid is primarily utilized in research related to type 2 diabetes, aiding in the exploration of its role in glucose metabolism and insulin sensitivity. -
PPARγ Agonist
MRL20 is a PPARγ constitutive and allosteric agonist that enhances the interaction between PPARγ and the co-activating peptide TRAP220, exhibiting an EC50 of 10 nM. Notably, even when covalently inhibited in its constitutive pocket by GW9662 or T0070907, MRL20 can maintain its ability to facilitate the PPARγ-TRAP220 interaction, with subsequent EC50 values of 176 nM and 440 nM, respectively. This compound does not completely inhibit cell activation, making MRL20 a valuable tool for investigating the allosteric regulatory mechanisms of PPARγ in various biological contexts. -
PPAR Agonist
ZLY032 is a dual agonist of FFA1 and PPARδ, primarily targeting these important nuclear receptors involved in metabolic regulation. This compound demonstrates significant activity in enhancing glucose and lipid metabolism, offering potential benefits in alleviating liver fibrosis. ZLY032 is of particular interest for research applications related to metabolic disorders and liver health. -
Pparδ Agonist
Pparδ Agonist 7 is a highly potent agonist of peroxisome proliferator-activated receptor delta (Pparδ), a critical component in the regulation of metabolic homeostasis, inflammation, and cell growth and differentiation. This compound is particularly relevant for research applications related to non-alcoholic fatty liver disease (NAFLD). By modulating Pparδ activity, Pparδ Agonist 7 can provide insights into therapeutic strategies for metabolic disorders and associated inflammatory conditions. -
Pparδ Agonist
PPARδ Agonist 8 is a potent agonist targeting the peroxisome proliferator-activated receptor delta (PPARδ), a crucial member of the nuclear receptor transcription factor superfamily. This compound facilitates the regulation of metabolic homeostasis, inflammation, and cellular differentiation, making it valuable for studying various biological processes. PPARδ Agonist 8 shows promise in research related to non-alcoholic fatty liver disease (NAFLD), contributing to understanding and potential therapeutic strategies for metabolic disorders. -
ATX Inhibitor/PPARγ Agonist
EL244 is a dual inhibitor of Autotaxin (ATX), with an IC50 of 50 nM, and a selective agonist of PPARγ, exhibiting an IC50 of 1.3 μM. This compound shows low cytotoxicity in human HepG2 cells, with an EC50 of 81.2 μM, and minimal inhibition of the cardiac hERG potassium channel (12% at 25 μM). EL244 effectively reduces pulmonary Lysophosphatidic Acid (LPA) levels, mitigates fibrosis, and enhances respiratory function in vivo, making it a valuable tool for the study of idiopathic pulmonary fibrosis and interstitial lung disease (ILD). -
PPAR Agonist
E-3030 free acid is a potent dual agonist of peroxisome proliferator-activated receptor (PPAR) alpha and PPAR gamma. This compound demonstrates significant antidiabetic and lipid-modulating activities by effectively reducing blood glucose, triglycerides, non-esterified fatty acids, and insulin levels, while enhancing adiponectin levels. E-3030 has been shown to improve glucose tolerance and exhibit remarkable triglyceride and non-high-density lipoprotein cholesterol-lowering effects in various animal models, making it a valuable tool for metabolic research and drug discovery. -
PPARγ agonist
L-796449 is a potent agonist of the peroxisome proliferator-activated receptor gamma (PPARγ). It exhibits neuroprotective properties, making it valuable for investigating therapeutic strategies in stroke research. Its ability to activate PPARγ may provide insights into mechanisms underlying neuroinflammation and tissue preservation following ischemic events.
